Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 6
2004 5
2005 8
2006 8
2007 33
2008 27
2009 9
2010 10
2011 8
2012 5
2013 9
2014 6
2015 11
2016 12
2017 11
2018 11
2019 23
2020 27
2021 37
2022 20
2023 24
2024 17
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

288 results

Results by year

Filters applied: . Clear all
Page 1
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Lanino L, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Consagra A, Musto P, Cilloni D, Oliva EN, Palmieri R, Poloni A, Califano C, Capodanno I, Itri F, Elena C, Fozza C, Pane F, Pelizzari AM, Breccia M, Di Bassiano F, Crisà E, Ferrero D, Giai V, Barraco D, Vaccarino A, Griguolo D, Minetto P, Quintini M, Paolini S, Sanpaolo G, Sessa M, Bocchia M, Di Renzo N, Diral E, Leuzzi L, Genua A, Guarini A, Molteni A, Nicolino B, Occhini U, Rivoli G, Bono R, Calvisi A, Castelli A, Di Bona E, Di Veroli A, Ferrara F, Fianchi L, Galimberti S, Grimaldi D, Marchetti M, Norata M, Frigeni M, Sancetta R, Selleri C, Tanasi I, Tosi P, Turrini M, Giordano L, Finelli C, Pasini P, Naldi I, Santini V, Della Porta MG; Fondazione Italiana Sindromi Mielodisplastiche (FISiM) Clinical network (https://www.fisimematologia.it/). Lanino L, et al. Among authors: galimberti s. Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24. Am J Hematol. 2023. PMID: 37222267 Free article. No abstract available.
Editorial: Measurable residual disease in hematologic malignancies.
Buccisano F, Palmieri R, Guzman ML, Galimberti S. Buccisano F, et al. Among authors: galimberti s. Front Oncol. 2023 May 10;13:1204393. doi: 10.3389/fonc.2023.1204393. eCollection 2023. Front Oncol. 2023. PMID: 37234991 Free PMC article. No abstract available.
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.
Chatzikonstantinou T, Scarfò L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, Kotaskova J, Demosthenous C, Smolej L, Mulligan S, Alcoceba M, Al-Shemari S, Aurran-Schleinitz T, Bacchiarri F, Bellido M, Bijou F, Calleja A, Medina A, Khan MA, Cassin R, Chatzileontiadou S, Collado R, Christian A, Davis Z, Dimou M, Donaldson D, Santos GD, Dreta B, Efstathopoulou M, El-Ashwah S, Enrico A, Fresa A, Galimberti S, Galitzia A, García-Serra R, Gimeno E, González-Gascón-Y-Marín I, Gozzetti A, Guarente V, Guieze R, Gogia A, Gupta R, Harrop S, Hatzimichael E, Herishanu Y, Hernández-Rivas JÁ, Inchiappa L, Jaksic O, Janssen S, Kalicińska E, Laribi K, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou E, Koren-Michowitz M, Kotsianidis I, Kreitman RJ, Labrador J, Lad D, Levin MD, Levy I, Longval T, Lopez-Garcia A, Marquet J, Martin-Rodríguez L, Maynadié M, Maslejova S, Mayor-Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Murru R, Nath UK, Navarro-Bailón A, Oliveira AC, Olivieri J, Oscier D, Panovska-Stavridis I, Papaioannou M, Papajík T, Kubova Z, Phumphukhieo P, Pierie C, Puiggros A, Rani L, Reda G, Rigolin GM, Ruchlemer R, Daniel de Deus Santos M, Schipani M, Schiwit… See abstract for full author list ➔ Chatzikonstantinou T, et al. Among authors: galimberti s. EClinicalMedicine. 2023 Nov 15;65:102307. doi: 10.1016/j.eclinm.2023.102307. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 38033506 Free PMC article.
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.
Sorgiovanni I, Del Giudice ML, Galimberti S, Buda G. Sorgiovanni I, et al. Among authors: galimberti s. Pharmaceuticals (Basel). 2025 Jan 22;18(2):145. doi: 10.3390/ph18020145. Pharmaceuticals (Basel). 2025. PMID: 40005960 Free PMC article. Review.
COVID-19: the new challenge for rheumatologists. First update.
Ferro F, Elefante E, Puxeddu I, Baldini C, Bartoloni E, Baratè C, Galimberti S, Talarico R, Mosca M, Bombardieri S. Ferro F, et al. Among authors: galimberti s. Clin Exp Rheumatol. 2020 May-Jun;38(3):373-382. doi: 10.55563/clinexprheumatol/yvn0nh. Epub 2020 May 26. Clin Exp Rheumatol. 2020. PMID: 32452355 Free article. No abstract available.
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahme R, Bertoli S, Fianchi L, Micol JB, Gottardi M, Peterlin P, Galimberti S, Thomas X, Rizzuto G, Legrand O, Rondoni M, Raffoux E, Bertani G, Caulier A, D'Argenio M, Bonmati C, Billio A, Lejeune C, Scappini B, Pigneux A, Zappasodi P, Recher C, Grimaldi F, Ades L, Lemoli RM. Cluzeau T, et al. Among authors: galimberti s. Blood Adv. 2025 Feb 25;9(4):752-758. doi: 10.1182/bloodadvances.2024014279. Blood Adv. 2025. PMID: 39454204 Free PMC article.
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Olivieri J, Marcheselli L, Guerra L, Ferrero S, Arcaini L, Cavallo F, Kovalchuk S, Skrypets T, Del Giudice I, Chauvie S, Patti C, Stelitano C, Ricci F, Pinto A, Margiotta Casaluci G, Zilioli VR, Merli A, Ladetto M, Bolis S, Pavone V, Chiarenza A, Arcari A, Anastasia A, Dondi A, Mannina D, Federico M; Fondazione Italiana Linfomi. Luminari S, et al. Among authors: galimberti s. J Clin Oncol. 2022 Mar 1;40(7):729-739. doi: 10.1200/JCO.21.01234. Epub 2021 Oct 28. J Clin Oncol. 2022. PMID: 34709880 Clinical Trial.
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis.
Cassano Cassano R, Genovesi D, Vergaro G, Giorgetti A, Aimo A, Del Giudice ML, Galimberti S, Emdin M, Buda G. Cassano Cassano R, et al. Among authors: galimberti s. Eur J Clin Invest. 2024 Oct;54(10):e14270. doi: 10.1111/eci.14270. Epub 2024 Jul 17. Eur J Clin Invest. 2024. PMID: 39021058
288 results